Novolizer Salbutamol 100 microgrammes/dose

DRUG2 trials

Sponsors

Glaxosmithkline Research & Development Limited

Conditions

Chronic Obstructive Pulmonary Disease

Phase 3

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

RecruitingCTIS2024-520417-41-00

Glaxosmithkline Research & Development LimitedChronic Obstructive Pulmonary Disease

Start: 2026-01-07Target: 327Updated: 2026-01-20

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.

RecruitingCTIS2024-520418-22-00

Glaxosmithkline Research & Development LimitedChronic Obstructive Pulmonary Disease

Start: 2026-01-20Target: 453Updated: 2026-01-09